Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05984758
Other study ID # 21PL04
Secondary ID IRAS
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 1, 2024
Est. completion date October 1, 2026

Study information

Verified date March 2024
Source Institute of Child Health
Contact Ameenat Solebo
Phone +44 20 3987 2162
Email a.solebo@ucl.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study seeks to describe, for children undergoing uveitis surveillance following a new diagnosis of juvenile idiopathic arthritis, the feasibility metrics of undertaking a randomised comparative study of routine slit lamp examination (SLE) versus imaging based (anterior segment optical coherence tomography, OCT) surveillance in order to inform the development of a larger multi-centre trial.


Description:

This study will compare imaging-based surveillance to routine clinical surveillance for uveitis in children with juvenile idiopathic arthritis (JIA) in order to support the design of a future study. Childhood uveitis is a rare inflammatory eye disease. Half of all children with uveitis also have a joint disorder: juvenile idiopathic arthritis (or JIA). Children with JIA must travel to a specialist centre every three months to have eye examinations in an attempt to pick uveitis up early enough to prevent visual loss. Optical coherence tomography (OCT) is a non-contact non-irradiating imaging modality. The investigators have recently demonstrated that novel application of OCT for uveitis detection in children is feasible, acceptable to families, repeatable, sensitive, and specific. The investigators have also found that families welcome the objectivity of imaging-based diagnosis. Standardised operating protocols for image acquisition and analysis have been developed across three imaging platforms (Optovue, Casia and Heidelberg OCT machines). The investigators will be undertaking a feasibility study which compares routine clinical examination based uveitis surveillance to imaging based surveillance in order to provide the necessary information to address this issue in a larger scale clinical trial of clinical and cost-effectiveness, and explore issues around the impact of objective disease metrics on family perceptions of disease and treatment, as well as the perceptions of children, families and clinical staff on the use of automated diagnostic tools.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date October 1, 2026
Est. primary completion date July 1, 2026
Accepts healthy volunteers No
Gender All
Age group 2 Years to 12 Years
Eligibility Inclusion Criteria: - Patients newly diagnosed (within preceding 12 months) with JIA who are eligible for uveitis surveillance - Aged 2-12 years Exclusion Criteria: - A previous / existing diagnosis of uveitis - Any co-existing ocular or neurological abnormality which impacts on current corrected visual function, or could impact on future corrected visual function - Developmental/learning difficulties that preclude concordance with examination / informed assent

Study Design


Intervention

Diagnostic Test:
AS-OCT imaging
Image acquisition with the Optovue RTVue OCT and the Heidelberg Spectralis OCT2 machines
Slit lamp examination
SLE of anterior chamber

Locations

Country Name City State
United Kingdom Great Ormond Street Hospital London

Sponsors (2)

Lead Sponsor Collaborator
Institute of Child Health Great Ormond Street Hospital for Children NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other New diagnoses Number of new diagnoses of uveitis / Number of new diagnosis of other visual/ocular problems 12months
Primary Proportion of patients who meet the eligibility criteria Feasibility data for larger scale study 18Months
Primary Number of eligible patients recruited Feasibility data for larger scale study 18Months
Primary Proportion of patients that withdraw due to loss of consent or are lost to follow-up Feasibility data for larger scale study 18Months
Secondary Success Success rates (ie agreement with routine clinical examination, set at 100% for routine examination arm, and analysed at 6 months and 12 months milestones for OCT arm) 12Months
Secondary Pediatric quality of life inventory (PedsQL) child self-report Health related quality of life, through child self-report, items linearly score on 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life) 12Months
Secondary Visual analogue scoring (VAS) of examination procedures Scale running from 0 - 100, with higher score meaning better experience as reported by child 12Months
See also
  Status Clinical Trial Phase
Completed NCT02776735 - An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Phase 2
Active, not recruiting NCT03092427 - Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA) N/A
Not yet recruiting NCT05545098 - MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
Not yet recruiting NCT03833609 - Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis N/A
Completed NCT02524340 - Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
Recruiting NCT01434082 - Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis N/A
Completed NCT04671524 - The Effect of Improvement in Function on Foot Pressure, Balance and Gait in Children With Upper Extremity Affected N/A
Recruiting NCT04167488 - Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy N/A
Recruiting NCT04205500 - Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis N/A
Terminated NCT01694264 - Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα Phase 3
Completed NCT02824978 - Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
Active, not recruiting NCT03841357 - Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) Phase 3
Completed NCT03833271 - The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary Early Phase 1
Completed NCT01455701 - A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA) Phase 1
Completed NCT05031104 - Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis N/A
Not yet recruiting NCT01436019 - Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis N/A
Recruiting NCT05609630 - Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. Phase 3
Recruiting NCT05696340 - Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers
Recruiting NCT05545839 - Transition to Adulthood Through Coaching and Empowerment in Rheumatology N/A
Completed NCT05436301 - Turkish Validity and Reliability of Pain Catastrophizing Scale-Child (PCS-C)